Incidence and risk factors for tuberculosis in hiv-infected patients while on antiretroviral treatment in cambodia

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 107, Issue 4, 2013, Pages 235-242

  Choun, Kimcheng ^a   Thai, Sopheak ^a   Pe, Reaksmey ^a   Lorent, Natalie ^a,b   Lynen, Lutgarde ^b   van Griensven, Johan ^a,b  

^a Sihanouk Hospital Center of HOPE   (Cambodia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral treatment; Asia; HIV; Incidence; Risk factor; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; ALGORITHM; ANTIRETROVIRAL THERAPY ASSOCIATED TUBERCULOSIS; ARTICLE; BODY MASS; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; UNDERWEIGHT; WORLD HEALTH ORGANIZATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CAMBODIA; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84880824857     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trt001     Document Type: Article

References (42)

1. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-29.
2. World Health Organization. Global Tuberculosis Control 2009. Epidemiology, Strategy, Financing. Geneva, Switzerland: WHO; 2009.
3. Lawn SD, Wood R, De Cock KM et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489-98.
4. Miranda A, Morgan M, Jamal L et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One. 2007;2:pe826.
5. Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis. 2005;41:1783-6.
6. Bonnet MM, Pinoges LL, Varaine FF et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS. 2006;20:1275-9.
7. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005;19:1113-24.
8. World Health Organization. Priority research questions for TB/HIV in HIVprevalent and resource-limited settings. Geneva, Switzerland: WHO; 2010.
9. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO; 2011.
10. Ait-Khaled N, Alarcon E, Bissell K et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13:927-35.
11. National Tuberculosis Program (CENAT).Annual Report 2010. Phnom Penh, Cambodia: Ministry of Health; 2010.
12. National Tuberculosis Program (CENAT). National Health Strategic Plan for Tuberculosis Control in the Kingdom of Cambodia 2011-2015. Phnom Penh, Cambodia: Ministry of Health; 2012.
13. Cain KP, McCarthy KD, Heilig CM et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010; 362:707-16.
14. National Center for HIV/AIDS DaSN. Annual Report 2010. Phnom Penh, Cambodia: Ministry of Health; 2010.
15. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2006 Revision. Geneva, Switzerland: WHO; 2006.
16. Thai S, Koole O, Un P et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health. 2009; 14:1048-58.
17. van Griensven J, Thai S. Predictors of immune recovery, the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg. 2011; 105:694-703.
18. Koole O, Thai S, Khun KE et al. Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS One. 2011;6:e18502.
19. Phan V, Thai S, Choun K et al. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One. 2012;7:e30647.
20. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd edn. Geneva, Switzerland: WHO; 2003.
21. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva, Switzerland: WHO; 2006.
22. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th edn. Geneva, Switzerland: WHO; 2010.
23. Kranzer K, Lewis JJ, White RG et al. Antiretroviral treatment cohort analysis using time-update CD4 counts: assessment of bias with different analysis methods. PLoS one. 2011;6:pe27763.
24. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-63.
25. Lawn SD, Myer L, Edwards D et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-25.
26. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011;56:349-55.
27. Rajasekaran S, Raja K, Jeyaseelan L et al. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile. Indian J Tuberc. 2009;56:69-76.
28. Golub JE, Saraceni V, Cavalcante SC et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-8.
29. Pednekar MS, Hakama M, Hebert JR et al. Association of body mass index with all-cause and cause-specific mortality: findings from a prospective cohort study in Mumbai (Bombay), India. Int J Epidemiol. 2008;37:524-35.
30. Leung CC, Lam TH, Chan WM et al. Lower risk of tuberculosis in obesity. Arch Intern Med. 2007;167:1297-304.
31. Lonnroth K, Williams BG, Cegielski P et al. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39:149-55.
32. Hanrahan CF, Golub JE, Mohapi L et al. Body mass index and risk of tuberculosis and death. AIDS. 2010;24:1501-8.
33. Nicholas S, Sabapathy K, Ferreyra C et al. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr. 2011;57:311-8.
34. Kowalska JD, Mocroft A, Blaxhult A et al. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retroviruses. 2007;23:1183-8.
35. Brinkhof MW, Egger M, Boulle A et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007;45:1518-21.
36. Fenner L, Forster M, Boulle A et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis. 2011;15:620-7.
37. Dembele M, Saleri N, Carvalho AC et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:318-23.
38. Seyler C, Toure S, Messou E et al. Risk factors for active tuberculosis in adults on highly active antiretroviral therapy in Africa. AIDS. 2006; 20:1463-5.
39. Lawn SD, Brooks SV, Kranzer K et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8:e1001067.
40. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 Revision. Geneva, Switzerland: WHO; 2010.
41. Lynen L, An S, Koole O et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr. 2009;52:40-8.
42. Lawn SD. Pre-screening with GeneXpert MTB/RIF may increase use of isoniazid preventive therapy in antiretroviral programmes. Int J Tuberc Lung Dis. 2011;15:1272-3